Abbisko Cayman Limited (2256.HK)
HKD 4.46
(-3.67%)
HKD 4.46
(-3.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -410.99 Million CNY | 13.71% |
| 2022 | -492.62 Million CNY | 73.54% |
| 2021 | -1.79 Billion CNY | -158.7% |
| 2020 | -696.97 Million CNY | -453.42% |
| 2019 | -96.4 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 123.64 Million CNY | 0.0% |
| 2024 Q1 | 123.64 Million CNY | 189.07% |
| 2023 Q4 | -138.81 Million CNY | 0.0% |
| 2023 FY | - CNY | 13.71% |
| 2023 Q3 | -138.81 Million HKD | -22.24% |
| 2023 Q2 | -113.56 Million CNY | 0.0% |
| 2023 Q1 | -113.56 Million CNY | 19.12% |
| 2022 Q3 | -140.41 Million CNY | -32.59% |
| 2022 Q2 | -105.89 Million CNY | 0.0% |
| 2022 FY | - CNY | 73.54% |
| 2022 Q4 | -140.41 Million CNY | 0.0% |
| 2022 Q1 | -105.89 Million CNY | -2.57% |
| 2021 Q1 | -120.7 Million CNY | 0.0% |
| 2021 Q3 | -103.24 Million CNY | 59.77% |
| 2021 FY | - CNY | -158.7% |
| 2021 Q4 | -103.24 Million CNY | 0.0% |
| 2021 Q2 | -256.63 Million CNY | -112.62% |
| 2020 Q1 | -54.08 Million CNY | 0.0% |
| 2020 FY | - CNY | -453.42% |
| 2019 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 550.48% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 184.428% |